NCT07713732RecruitingPhase 1
TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors
An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors
Source: ClinicalTrials.gov · Last updated 1 Oct 2026
Brief summary (registry, in English)
The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TLN-499 in combination with venetoclax in participants with relapsed/refractory solid tumors.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 9 Jul 2026
- Start date
- 5 Aug 2026
- Primary completion date
- 29 Aug 2030
- Lead sponsor
- Treeline Biosciences, Inc.
- Diseases
- Mesothelioma, Neuroendocrine tumours, Lung cancer, Sarcoma
- NCT number
- NCT07713732
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 120
- From 5 Aug 2026 to the primary completion date, 29 Aug 2030
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Major surgery or severe trauma within 4 weeks before first dose
- Use of prohibited concomitant medications
- Previous conditions that would interfere with study assessments or safety
Other illness
- Significant uncontrolled medical conditions preventing study participation
Other
- Active brain metastases
Who the study is looking for
- Adults ≥18 years of age
- Histologically confirmed relapsed/refractory SCLC, neuroendocrine cancer, malignant pleural mesothelioma, or synovial sarcoma
- Measurable disease per RECIST v1.1 or mRECIST
- ECOG performance status 0-1
- Adequate hematologic, hepatic, renal, and coagulation function.
- Life expectancy ≥12 weeks
- Signed informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| COBL Clinical Trials - Chris O'Brien Lifehouse Coordinator of this site? Confirm its status | Camperdown | Australia | Not yet recruiting |
| Cabrini Hospital - Malvern Coordinator of this site? Confirm its status | Malvern | Australia | Not yet recruiting |
| Linear Clinical Research Coordinator of this site? Confirm its status | Nedlands | Australia | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.